LRRK2 and melanoma: Loss of heterozygosity of PARK2, LRRK2 mutations causing neuronal cell death and neurotoxicity, BRAF kinase alterations, and PARK7 oncogene activation with subsequent melanoma development are possible underpinning genetic pathophysiologiy [11, 34].